Buy Dr Reddys Laboratories: target of Rs 1430: ICICI Securities

Moneycontrol • 6 days ago

Original source

Key Investment Pillars

  • New launches in the US, such as sugammadex and bosutinib, are driving revenue growth and improving gross margins.
  • A better product mix, with a higher contribution from branded businesses, is supporting margin expansion.
  • The company's base business, excluding gRevlimid, is growing in double digits, driven by new product launches and a strong performance in the India business.
  • The relaunch of semaglutide in Canada and the approval of biosimilar abatacept in the US are expected to be key catalysts for growth.

Thesis Validation Checklist

  • Investors should watch for the successful relaunch of semaglutide in Canada and the approval of biosimilar abatacept in the US.
  • The company's ability to sustain its current US sales run-rate and improve its EBITDA margin will be key to the investment thesis.
  • The progress of the company's biosimilars pipeline, including the launch of rituximab and pembrolizumab, will be an important indicator of the company's growth prospects.
  • The company's ability to manage regulatory risks and maintain its competitive position in the US and India markets will be crucial to the investment thesis.